The neurovasculature as a target in temporal lobe epilepsy

Yvonne Reiss,Sebastian Bauer,Bastian David,Kavi Devraj,Elif Fidan,Elke Hattingen,Stefan Liebner,Nico Melzer,Sven G. Meuth,Felix Rosenow,Theodor Rüber,Laurent M. Willems,Karl H. Plate
DOI: https://doi.org/10.1111/bpa.13147
IF: 7.611
2023-01-05
Brain Pathology
Abstract:Targeting vascular dysfunction at the neurovascular unit in epilepsy and neurological diseases. The blood–brain barrier (BBB) is a physiological barrier maintaining a specialized brain micromilieu that is necessary for proper neuronal function. Endothelial tight junctions and specific transcellular/efflux transport systems provide a protective barrier against toxins, pathogens, and immune cells. The barrier function is critically supported by other cell types of the neurovascular unit, including pericytes, astrocytes, microglia, and interneurons. The dysfunctionality of the BBB is a hallmark of neurological diseases, such as ischemia, brain tumors, neurodegenerative diseases, infections, and autoimmune neuroinflammatory disorders. Moreover, BBB dysfunction is critically involved in epilepsy, a brain disorder characterized by spontaneously occurring seizures because of abnormally synchronized neuronal activity. While resistance to antiseizure drugs that aim to reduce neuronal hyperexcitability remains a clinical challenge, drugs targeting the neurovasculature in epilepsy patients have not been explored. The use of novel imaging techniques permits early detection of BBB leakage in epilepsy; however, the detailed mechanistic understanding of causes and consequences of BBB compromise remains unknown. Here, we discuss the current knowledge of BBB involvement in temporal lobe epilepsy with the emphasis on the neurovasculature as a therapeutic target.
pathology,neurosciences,clinical neurology
What problem does this paper attempt to address?